With approximately $655 million in available liquidity as of Q1 2026, AbCellera maintains a strong cash position to execute its strategy. The company has reached a cumulative total of 104 partner-initiated program starts with downstream partners and has 19 molecules that have reached the clinic. In June 2026, AbCellera entered a collaboration with Jazz Pharmaceuticals for T-cell engaging multispecific antibodies, receiving $56 million upfront plus potential milestone payments up to $792 million per program.
Cyborg Score Rationale
Q1 2026 revenue jumped to $8.3M, nearly doubling year over year, while the company maintained $655M in liquidity; positive interim Phase 1 data for ABCL635 showed clean safety and biomarkers supporting once-monthly dosing. Phase II results for ABCL635 are expected in Q3 2026. The company faces binary clinical trial risks but has substantial runway and validation of its discovery platform.
Top Insights
ABCL635 achieved robust NK3R target engagement at doses that were well-tolerated in healthy volunteers with a pharmacokinetic profile supporting once monthly dosing.
Q1 2026 revenue of $8.3M nearly doubled year-over-year, ahead of Wall Street consensus.
Jazz Pharmaceuticals collaboration with upfront of $56M and potential milestone payments demonstrates third-party validation of the antibody discovery platform.
Two additional development candidates, ABCL688 and ABCL386, are advancing into IND/CTA-enabling activities.
Named Competitors
REGENERON — Biopharmaceutical company developing antibody therapies
AMGEN — Global biopharmaceutical company with therapeutic antibodies
GENMAB — Antibody therapeutics platform company
Recent Developments
(June 2026) Announced preclinical research collaboration with Jazz Pharmaceuticals to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and solid tumors.
(May 2026) ABCL635 demonstrated favorable tolerability profile with no observed liver toxicity and achieved potent and sustained reductions in biomarkers of target engagement in Phase 1 interim data.
(February 2026) Full year 2025 revenue of $75.1 million earned with clinical programs advanced into trials.
Open the full interactive AbCellera Biologics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.